

What is claimed:

- 1) Use of a BCMAxCD3 bispecific antibody for the manufacture of a medicament for the treatment of a cancer in a subject, wherein the medicament is to be administered in combination with an anti-CD38 antibody, wherein the cancer is a multiple myeloma, and wherein:
 - a) the BCMAxCD3 bispecific antibody comprises a first heavy chain (HC1) of SEQ ID NO: 31, a first light chain (LC1) of SEQ ID NO: 32, a second heavy chain (HC2) of SEQ ID NO: 41 and a second light chain (LC2) of SEQ ID NO: 42; and
 - b) the anti-CD38 antibody comprises a heavy chain (HC) of SEQ ID NO: 12 and a light chain (LC) of SEQ ID NO: 13.
- 2) Use of an anti-CD38 antibody for the manufacture of a medicament for the treatment of a cancer in a subject, wherein the medicament is to be administered in combination with a BCMAxCD3 bispecific antibody, wherein the cancer is a multiple myeloma, and wherein:
 - a) the anti-CD38 antibody comprises a HC of SEQ ID NO: 12 and a LC of SEQ ID NO: 13; and
 - b) the BCMAxCD3 bispecific antibody comprises a HC1 of SEQ ID NO: 31, a LC1 of SEQ ID NO: 32, a HC2 of SEQ ID NO: 41 and a LC2 of SEQ ID NO: 42.
- 3) Use of a BCMAxCD3 bispecific antibody and an anti-CD38 antibody for the manufacture of medicaments for the treatment of a cancer in a subject, wherein the cancer is a multiple myeloma, and wherein:
 - a) the BCMAxCD3 bispecific antibody comprises a HC1 of SEQ ID NO: 31, a LC1 of SEQ ID NO: 32, a HC2 of SEQ ID NO: 41 and a LC2 of SEQ ID NO: 42; and
 - b) the anti-CD38 antibody comprises a HC of SEQ ID NO: 12 and a LC of SEQ ID NO: 13; wherein the BCMAxCD3 bispecific antibody and the anti-CD38 antibody are to be administered in combination.
- 4) The use of any one of claims 1-3, wherein the anti-CD38 antibody is to be administered to the subject prior to the BCMAxCD3 bispecific antibody being administered.
- 5) The use of any one of claims 1-4, wherein:
 - a) the multiple myeloma:
 - I. is a newly diagnosed multiple myeloma; or
 - II. is a relapsed or a refractory multiple myeloma; and/or
 - b) the multiple myeloma is a high-risk multiple myeloma.
- 6) The use of claim 5b), wherein the subject having the high-risk multiple myeloma has one or more chromosomal abnormalities comprising:
 - I. t(4;14)(p16;q32);
 - II. t(14;16)(q32;q23);
 - III. del17p;
 - IV. 1qAmp;

V. t(4;14)(p16;q32) and t(14;16)(q32;q23);

VI. t(4;14)(p16;q32) and del17p;

VII. t(14;16)(q32;q23) and del17p; or

VIII. t(4;14)(p16;q32), t(14;16)(q32;q23) and del17p, or any combination thereof.

- 7) The use of any one of claims 1-6, wherein:
 - a) the anti-CD38 antibody is to be administered at a dose of between 8 mg/kg and 16 mg/kg; and/or
 - b) wherein the BCMAxCD3 bispecific antibody and the anti-CD38 antibody are to be administered by an intravenous injection or wherein the BCMAxCD3 bispecific antibody is to be administered by an intravenous injection and the anti-CD38 antibody is to be administered by a subcutaneous injection.
- 8) The use of any one of claims 1-7, wherein the subject is a human.
- 9) The use of any one of claims 1-13, wherein the use further comprises one or more anti-cancer therapies are to be administered to the subject.
- 10) The use of claim 9, wherein the one or more anti-cancer therapies is selected from the group consisting of:
 - i) an autologous stem cell transplant (ASCT), radiation, surgery, a chemotherapeutic agent, an immunomodulatory agent and a targeted cancer therapy; or
 - ii) lenalidomide, thalidomide, pomalidomide, bortezomib, carfilzomib, elotuzumab, ixazomib, melphalan, prednisone or dexamethasone, or any combination thereof.
- 11) The use of any one of claims 1-10, wherein the anti-CD38 antibody is to be administered in a pharmaceutical composition comprising between 20 mg/mL to 120 mg/mL of the anti-CD38 antibody in 25 mM acetic acid, 60 mM sodium chloride, 140 mannitol and 0.04% w/v polysorbate-20 (PS-20); at pH 5.5.
- 12) The use of any one of claims 1-10, wherein the anti-CD38 antibody is to be administered in a pharmaceutical composition comprising:
 - i) between 5 mM and 15 mM histidine;
 - ii) between 100 mM and 300 mM sorbitol;
 - iii) between 0.01% w/v and 0.04 % w/v PS-20; and
 - iv) between 1 mg/mL and 2 mg/mL methionine, at a pH of 5.5-5.6.